PUBLIC COMPANY
saveABBVIE
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
- phase3A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- phase3A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
- —Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease
- phase2RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
- phase2RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
- phase1Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants
- phase1A Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move Through the Body of Healthy Adult Participants
🐶 Hiring Signal
News
- STAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in ChinaBig drugmakers tell U.S. House committee they will halt clinical trials at some hospitals in China.stat · 4h ago
- nChroma halves workforce, BioXcel lets execs goFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 13h ago
- AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing dealThere’s a party going on at DISCO Pharma’s European headquarters after the precision medicine biotech signed its second major pharma partnership of the year—first Amgen, now AbbVie.biospace · 21h ago
- AbbVie and Disco strike deal worth up to $2.54B for solid tumor targetsAbbVie is partnering with preclinical cancer biotech Disco Pharmaceuticals to build out its antibody-drug conjugate and T cell engager programs. The Cologne, Germany-based biotech will receive $40…endpoints · 21h ago
- 9 biotechs will cut at least half their California workforcesWorkforce reductions have hit over 1,000 biopharma employees in The Golden State year to date, with pink slips coming from small biotechs and large pharmas. Biotechs have been hit the hardest, with…biospace · 23h ago
- CTAD 2026: BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questionsAt the Clinical Trials on Alzheimer’s Disease Conference, BMS finally revealed early data for its Alzheimer’s disease psychosis trials of KarXT, marketed as Cobenfy in schizophrenia.biospace · 1d ago
- Pfizer leaps into ‘in vivo’ CAR-T with latest China dealThe potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.biopharma_dive · 1d ago
- Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safetySummit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population.biospace · 1d ago
- AbbVie busts a move with Disco in $2.5B dance aimed at bispecific discoveryAbbVie is twirling onto the dance floor with Disco Pharmaceuticals, offering up to $2.5 billion to work with the German platform company on cancer-targeted bispecific discovery.fiercebiotech · 1d ago
- Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlightThe FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…biospace · 1d ago
comments(0)
5-min edit window · permanent after that